Skip to main content
. 2016 May 9;7(24):36971–36987. doi: 10.18632/oncotarget.9235

Figure 5. Cleaved-Par-4 protein stability.

Figure 5

A. Endometrial cl-Par-4 cancer cells were treated or not with either 2μM MG-132 or 20μM for 24h and 50μg/ml cycloheximide was added 1-8h before the end of treatment. The protein level of cl-Par-4-myc was determined in treated cells using western blot analysis. GAPDH was used as a loading control. Results shown are representative of three independent experiments. B. Graph representing cl-Par-4 protein stability when using cycloheximide in combination or not with MG-132. C. Graph representing cl-Par-4 protein stability when using cycloheximide in combination or not with cisplatin. Results are mean ± S.E.M. of three independent experiments. *=P<0.05, **=P<0.01 and ***=P<0.001 when compared with corresponding mock-treated cells.